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Objectives: We evaluated the effects of daily supplementation with ubiquinol on gluteal muscle CoQ10 concentrations and related them to citrate synthase (CS) activities in fit Thoroughbreds. CS is an important Kreb's cycle enzyme and an indicator of oxidative phosphorylation status.
Study design: Randomised, controlled crossover study.
Methods: Six horses received either 1 g ubiquinol for 3 weeks followed by 21 days without supplement, or had a 3-week unsupplemented period followed by 3 weeks supplementation. Middle gluteal muscle biopsies were obtained at Day 0 (baseline), and after 10 and 21 days of each period. Muscle [CoQ10] was determined by HPLC with UV detection at 275 nm. CS was measured spectrophotometrically at 37°C and related to mitochondrial [CoQ10] . Results (mean AE s.d.) were analysed by 2-way RM ANOVA for effects of supplementation and time (P<0.05). Objectives: 1) To investigate the hypothesis that HGA and MCPAc serum concentrations correlate with muscle damage and differ between horses with varying severities of AM; 2) to estimate the half-life of HGA in affected horses.
Study design: Retrospective study.
Methods: 32 horses with detectable serum HGA were allocated to three groups according to pre-selected clinical signs: severe (typical AM presentation), mild and subclinical. Serum HGA and MCPAc concentrations and CK activity were measured, compared and correlated between groups. Serum HGA concentration was also measured in six horses (n = 2 hospitalised; n = 4 nonhospitalised) over time.
Results: Muscle fasciculations, myoglobinuria and paresis were the most commonly reported signs in the severe group (100%; n = 12/12). For the mild disease group, paresis was reported in 42% (n = 5/12) of cases and stiffness in 33% (n = 4/12). Serum CK activity was positively correlated with both HGA (rho = 0.46; P = 0.006) and MCPAc (rho = 0.74; P<0.0001). CK, HGA, MCPAc were significantly higher in severely affected horses compared with the other groups. Subclinically affected horses had significantly lower serum CK activity and HGA concentration (P = 0.01; P = 0.009) than the mildly affected horses. MCPAc was undetectable in either mild or subclinical groups. In hospitalised horses receiving treatment and fluid therapy, HGA serum half-life was 38 h (confidence interval: 35-67.2 h) while in nonhospitalised horses (HGA concentrations initially below 74 ng/mL), HGA was undetectable in serum after 15 days.
Main limitations: Lack of full clinical or pasture details for some horses.
Conclusions: Measurement of serum HGA and MCPAc discriminates horses with varying severities of AM and identifies subclinically-affected horses that might be at risk of developing AM. 
